Phosphate control in end-stage renal disease: Barriers and opportunities

Ahmed A. Waheed, Fernando Pedraza, Oliver Lenz, Tamara Isakova*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Abstract

Hyperphosphatemia is a nearly universal complication of endstage renal disease that is widely recognized as one of the most important and most challenging clinical targets to meet in the care of dialysis patients. Left untreated, it can lead to bone pain, pruritus and worsening secondary hyperparathyroidism. Data from observational studies demonstrate that an elevated serum phosphorus level is an independent risk factor for mortality, and that treatment with phosphate binders is independently associated with improved survival. Experimental studies provide support for the epidemiologic findings: phosphate excess promotes vascular calcification, induces endothelial dysfunction and may contribute to other emerging chronic kidney disease-specific mechanisms of cardiovascular toxicity. On the basis of this evidence, clinical practice guidelines recommend specific targets for serum phosphorus levels in the dialysis population. The purpose of this review is to summarize common challenges in meeting these targets and to identify potential opportunities for improvement.

Original languageEnglish (US)
Pages (from-to)2961-2968
Number of pages8
JournalNephrology Dialysis Transplantation
Volume28
Issue number12
DOIs
StatePublished - Dec 1 2013

Keywords

  • Dialysis
  • Phosphate binders
  • Phosphorus

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Fingerprint Dive into the research topics of 'Phosphate control in end-stage renal disease: Barriers and opportunities'. Together they form a unique fingerprint.

Cite this